New work out on breast cancer overdiagnosis after screening mammography among older women: acpjournals.org/doi/10.7326/M2…

In recognition of his innovation, George Goshua, MD MSc has been named a Young Explorer Award finalist by NOMIS & Science Magazine. Dr. Goshua shared how mathematical models can hold the key to equitable patient care in, "Napkin math can change the world." bit.ly/3sxA1HE

Congratulations and welcome to the newest members of the Yale IM Traditional Residency Program family!!! Can't wait to meet and work with you all in the near future. Yale Internal Medicine #MatchDay2024

Our recent review on targeted therapies in #MDS discussing current landscape and future directions tandfonline.com/doi/full/10.10…. Special thanks to Dr. Amer Zeidan MBBS,MHS ‏عامر زيدان and all co-authors for their guidance and support Yale IM Traditional Residency Program Yale Cancer Center YaleHematology

Excited to see this article with George Goshua, MD MSc out in Bulletin of the Atomic Scientists, where we explore how adding a health equity lens to valuation can help harness the potential of gene therapies around the world Yale School of Medicine Yale Internal Medicine Yale IM Traditional Residency Program Mark D. Siegel

.Kunal Potnis, MD reveals that at the current pricing, eltrombopag plus traditional immunosuppressive therapy is unlikely to be a cost-effective treatment for adults with severe aplastic anemia in the US. #ASH24 George Goshua, MD MSc YaleHematology Smilow Cancer Hospital ash.confex.com/ash/2024/webpr…

Great CCU block! ✅ Yale IM Traditional Residency Program Missing our fellows Dae Yong Park @OmarosisFugax

.Kunal Potnis, MD shares that at current pricing, ribociclib w endocrine therapy is not expected to be cost-effective compared to endocrine therapy alone for pts with HR+ HER2- early #breastcancer in the US. #ASCO25 George Goshua, MD MSc Smilow Cancer Hospital Yale School of Medicine OncoAlert YaleBreastCancer

We are now diving into the tumor-gut axis in the aRCC field as well; Lower levels of MAdCAM-1 in plasma are associated with more aggressive RCC & are one of the most promising prognostic biomarkers by Renee Maria Saliby ASCO David Braun Toni Choueiri, MD Yale Cancer Center Yale School of Medicine

Thank you Oncology Learning Network for the opportunity to discuss our team's recent #breastcancer cost-effectiveness work at #ASCO25